Trial Profile
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Acronyms SPARTAN
- Sponsors CoLucid Pharmaceuticals; Eli Lilly and Company
- 02 Jul 2022 Results of four pooled analysis from (NCT02439320, NCT02605174, NCT03962738, NCT03670810) published in the CNS Drugs
- 01 May 2022 Results of post-hoc pooled analysis of two studies (SAMURAI [NCT02439320] and SPARTAN [NCT02605174]) assessing details migraine disease characteristics and treatment outcomes after treatment with lasmiditan, published in the Current Medical Research and Opinion.
- 26 Apr 2022 Results of post-hoc analysis of 4 studies (AMURAI, SPARTAN, CENTURION, and MONONOFU) assessing the efficacy and safety of lasmiditan in patients with and without at least one triptan contraindication, published in the Pain and Therapy.